Analyst Activity – Citigroup Inc. Reiterates Outperform on CymaBay Therapeutics (NASDAQ:CBAY)

ME Staff
-
0

Analyst Ratings For CymaBay Therapeutics (NASDAQ:CBAY)

Today, Citigroup Inc. reiterated its Outperform rating on CymaBay Therapeutics (NASDAQ:CBAY) with a price target of $15.00.

There are 4 buy ratings, 1 strong buy rating on the stock.

The current consensus rating on CymaBay Therapeutics (NASDAQ:CBAY) is Buy (Score: 3.20) with a consensus target price of $10.50 per share, a potential 42.47% upside.

Some recent analyst ratings include

  • 7/20/2017-Citigroup Inc. Reiterated Rating of Outperform.
  • 7/17/2017-Ifs Securities Reiterated Rating of Strong-Buy.
  • 6/23/2017-Oppenheimer Holdings, Inc. initiated coverage with a Outperform rating.
  • 7/1/2016-Roth Capital initiated coverage with a Buy rating.

Recent Insider Trading Activity For CymaBay Therapeutics (NASDAQ:CBAY)
CymaBay Therapeutics (NASDAQ:CBAY) has insider ownership of 15.10% and institutional ownership of 36.87%.

  • On 9/6/2016 Robert James Wills, Director, bought 25,000 with an average share price of $2.43 per share and the total transaction amounting to $60,750.00. View SEC Filing
  • On 4/15/2016 Charles Mcwherter, VP, bought 3,000 with an average share price of $1.68 per share and the total transaction amounting to $5,040.00. View SEC Filing
  • On 4/5/2016 Sujal Shah, CFO, bought 55,000 with an average share price of $1.39 per share and the total transaction amounting to $76,450.00. View SEC Filing
  • On 4/4/2016 Sujal Shah, CFO, bought 22,000 with an average share price of $1.39 per share and the total transaction amounting to $30,580.00. View SEC Filing
  • On 9/11/2015 Carl Goldfischer, Director, sold 46,729 with an average share price of $2.74 per share and the total transaction amounting to $128,037.46. View SEC Filing
  • On 8/14/2015 Emster Kurt Von, Director, bought 90,000 with an average share price of $2.69 per share and the total transaction amounting to $242,100.00. View SEC Filing
  • On 7/20/2015 Emster Kurt Von, Director, bought 1,600,000 with an average share price of $2.81 per share and the total transaction amounting to $4,496,000.00. View SEC Filing

Recent Trading Activity for CymaBay Therapeutics (NASDAQ:CBAY)
Shares of CymaBay Therapeutics closed the previous trading session at 7.37 up +0.43 6.20% with 10,644,964 shares trading hands.